Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Radiotherapy on the MR-Linac, Imaging on the MR Linac.
- Who it may be relevant to
- Registry conditions: Rectal Cancer, Head and Neck Cancer, Liver Cancer, Breast Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Feasibility of Imaging and Radiotherapy on a Novel 1.5 T Hybrid Magnetic Resonance Imaging - Linear Accelerator System (MR-Linac)
Overview
This study investigates the feasibility of imaging and treatment on a novel 1.5 T MR-Linac radiotherapy hybrid device.
Detailed description
Novel hybrid devices combine magnetic resonance imaging (MRI) and a linear accelerator in a single device. The superior soft tissue contrast compared with cone-beam computed tomography based treatment and the possibility for daily plan adaptation promise a higher precision of treatment, better target volume coverage and normal tissue sparing. In a first step the present study will test the feasibility of imaging and treatment on the 1.5 T MR-Linac.
Interventions
- Radiation Radiotherapy on the MR-Linac
Radiotherapy is performed on the 1.5 T MR Linac - Diagnostic test Imaging on the MR Linac
Only imaging performed on the MR Linac
Primary outcome measures
- Feasibility of online MR guided Radiotherapy [Time frame: During every single patients treatment (i.e. between one to seven weeks after the first application of radiotherapy)]
Secondary outcome measures (1)
- Time analysis [Time frame: During every single patients treatment (i.e. between one to seven weeks after the first application of radiotherapy)]
Eligibility criteria
Inclusion criteria
- existing indication for radiation therapy
- minimum age 18 years, no upper age limit
- capacity for consent
- Informed consent
Exclusion criteria
- contraindication for MRI (claustrophobia, metallic implants not applicable for MRI
- pregnancy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Germany · 1 center
- University Hospital Tübingen, Department of Radiation Oncology — Tübingen
Publications
- Boeke S, Habrich J, Kubler S, Boldt J, Schick F, Nikolaou K, Kubler J, Gani C, Niyazi M, Zips D, Thorwarth D. Longitudinal assessment of diffusion-weighted imaging during magnetic resonance-guided radiotherapy in head and neck cancer. Radiat Oncol. 2025 Jan 29;20(1):15. doi: 10.1186/s13014-025-02589-9. PMID 39881423
- Potkrajcic V, Gani C, Fischer SG, Boeke S, Niyazi M, Thorwarth D, Voigt O, Schneider M, Monnich D, Kubler S, Boldt J, Hoffmann E, Paulsen F, Mueller AC, Wegener D. Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation. Curr Oncol. 2024 May 9;31(5):2679-2688. doi: 10.3390/curroncol31050203. PMID 38785484
Identifiers
NCT: NCT04172753 · 659/2017BO1